Navigation Links
Start of Phase II Study for Intranasal, Seasonal Influenza Vaccine deltaFLU
Date:1/13/2010

VIENNA, Austria, January 13 /PRNewswire/ --

- By Starting the Phase II Study for deltaFLU, AVIR Green Hills AG has Accomplished yet Another Milestone in the Development of this Novel Influenza Vaccine. Completion of this Clinical Phase II Study is Envisaged for Spring 2010

- The Positive Results Obtained in the Previous Clinical Phase I Study will be Published in the Renowned "Journal of Infectious Diseases" on 15 January 2010

AVIR Green Hills Biotechnology, the innovative biotech company based in Vienna, has started the New Year by embarking on the first clinical phase II study for the seasonal vaccine deltaFLU. The study will be carried out at the Medical University of Vienna. With this step, AVIR Green Hills has set yet another important milestone in the development of effective and modern influenza vaccines.

Start of clinical phase II study

In a randomized double blind study, the vaccine will be administered intranasally to 48 volunteers.

"In double blind studies, neither the administering physician (and/or the commissioning party) nor the volunteers know who gets the placebo. Moreover, none of them knows which sprays contain the tested vaccine and which contain the placebo," explains Franz Groiss, who is in charge of managing clinical studies at AVIR Green Hills Biotechnology. The study will be headed by Volker Wacheck and carried out at the Department of Clinical Pharmacology at the Vienna General Hospital.

Aim of phase II study

The aim of the phase II study is to optimize the vaccine dose and to substantiate the efficiency of the vaccine and its ability to trigger an immune response.


'/>"/>

SOURCE AVIR Green Hills Biotechnology AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD)
2. JumpStart Invests in Checkpoint Surgical
3. Prodromal Symptoms Warn of Hereditary Angioedema Attacks, Give Patients Time to Start Therapy and Decrease Morbidity
4. Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
5. Dong-A PharmTech Co., Ltd. Announces Start of Phase III Trials for Udenafil, Its New Erectile Dysfunction Drug Under Development
6. AMT Starts Development LPLChip(TM) With Progenika
7. American Association for Homecare Proposes Strong Anti-Fraud Measures in Medicare, Applauds HHS Testimony Today That Pledges to "Stop Fraud Before it Starts"
8. Patients who Participated in Pleio GoodStart(TM) Refilled 30% Sooner and 40% More, Averaging 2 Additional Rx Refills per Patient
9. R-Tech Ueno Starts Early Phase II Clinical Trial for RK-023
10. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Melanoma Cancer Clinical Trial
11. Cytopias CYT387 Receives FDA Clearance to Start US Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015 Gem Pharmaceuticals announced today that ... enrolled into the Company,s Phase 2 clinical trial.  This ... Gem,s lead compound, GPX-150 (an investigational medication), in approximately ... disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/22/2015)... CLEVELAND , Jan. 22, 2015  ViewRay™, a privately ... entered into an exclusive distributor agreement with ITOCHU Corporation ... radiation therapy system for the treatment of cancer in ... (me-rid-i-an) system, is the world,s first and only MRI-guided ...
(Date:1/22/2015)... Jan. 22, 2015  ResMed Inc. (NYSE: RMD ) ... Revenue for the quarter was $423.0 million, a 10 percent ... 14 percent increase on a constant currency basis). Net income ... the quarter ended December 31, 2013. Diluted earnings per share ...
Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11
(Date:1/22/2015)... (PRWEB) January 22, 2015 Blue Cross and ... Minnesotans who exemplify what it means to “Live Fearless.” ... for people to share their stories about how they or ... simply inspired others by living in the moment. By telling ...
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo and ... federal multidistrict litigation underway in U.S. District Court, District ... Order dated January 20th, the Court has remanded a ...
(Date:1/22/2015)... 22, 2015 A study recently ... flagship journal Medicine & Science in Sports & ... may help reduce gastrointestinal (GI) problems associated with ... Participants in the double-blind, placebo-controlled study took 10 ...
(Date:1/22/2015)... 2015 Payday lending practices in four ... cause financial distress to the states that permit them, ... University’s Center on Race and Wealth. , While they ... payday loans at the same time substantially depress economic ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Lower-Auto-Insurance.com has released a ... kit in a car for reducing the costs of an ... will also be able to get lower prices for their vehicle ... an important role in determining policy costs. Because of this, ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
... diagnostic procedures in cardiology. The idea of publishing an ... of European cardiovascular imagers, is therefore long awaited. The ... with a patient rather than technology-based approach, helping clinicians ... aid of imaging. The book is divided ...
... ... of Fortune 1000 employers strongly indicates that wellness programs have a positive impact on ... ... of Fortune 1000 companies reveals that 78 percent of employers have improved employee participation ...
... , SCHAFFHAUSEN, Switzerland, Dec. 16 Tyco International Ltd. ... Michael E. Daniels for election to the Tyco Board of ... 2010. , Daniels, 55, is Senior Vice President of ... In this role, he has worldwide responsibility for IBM,s Global ...
... , BOCA RATON, Fla., Dec. 16 Dale Buchanan, owner ... have a weight loss contest for his students in the new year. The ... own prize or against each other. They will be losing weight to raise ... , "For every pound each student of mine loses between January 4 ...
... to 11-month interval lessens complication risks , TUESDAY, Dec. 15 (HealthDay ... such a profound impact on your life that you just can,t ... suggests that you might want to wait at least six months ... be even better. , The study found that when the ...
... ... received a further 1.6 million Euro in capital funding to scale up production and ... for this promising new technology. The capital was invested by LD Pensions and Unisense A/S ... ...
Cached Medicine News:Health News:The European Society of Cardiology Textbook of Cardiovascular Imaging puts patient at center 2Health News:The European Society of Cardiology Textbook of Cardiovascular Imaging puts patient at center 3Health News:Hallmark Insights' Employer Survey Reveals Cost-Savings Benefits of Health & Wellness Programs 2Health News:Tyco International Files Preliminary Proxy Proposing Election of New Director 2Health News:Fitness Trainer Motivates Clients with Weight Loss to Help Raise Money for Animal Shelter 2Health News:For Babies' Sake, Pregnancy Spacing Matters 2Health News:For Babies' Sake, Pregnancy Spacing Matters 3Health News:Increased Capital Funding for Unisense FertiliTech A/S Will Help Meet Demand for New Assisted Reproduction Device 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: